- Home
- RSF vs IMMP Comparison
RSF vs IMMP Comparison
Compare RSF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | IMMP |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 58.2M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RSF | IMMP |
|---|---|---|
| Price | $14.69 | $0.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 16.9K | ★ 2.7M |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $417.85 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $0.32 |
| 52 Week High | $15.36 | $3.53 |
Technical Indicators
Market Signals| Indicator | RSF | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 13.85 |
| Support Level | $14.62 | N/A |
| Resistance Level | $14.80 | $0.39 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 46.67 | 11.15 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.